How accurate are the longer-term projections of overall survival for cancer immunotherapy for standard versus more flexible parametric extrapolation methods?

References

• Quinn C, Garrison LP, Pownell AK, et al. Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective. J Immunother. 2020;8(2):e000648.
   Web of Science ®Google Scholar
• Latimer N, editor. Estimating survival benefit for health technology assessment. New challenges presented by immuno-oncology treatments? Basel:BBS/PSI 1-Day Scientific Meeting; 2017. Available from: http://bbs.ceb-institute.org/wp-content/uploads/2017/06/Session4_NicholasLatimer.pdf
   Google Scholar
• Dine J, Gordon R, Shames Y, et al. Immune checkpoint inhibitors: an innovation in immunotherapy for the treatment and management of patients with cancer. Asia Pac J Oncol Nurs. 2017;4(2):127–135.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889–1894.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. 5 The reference case 2013. [02 May 2021]. Available from: https://www.nice.org.uk/process/pmg9/chapter/the-reference-case.
   Google Scholar
• Latimer N. NICE DSU Technical Support Document 14: survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data; 2011. [Last updated 2012 Apr; cited 2021 May 2]. Available from: http://nicedsu.org.uk/technical-support-documents/survival-analysis-tsd/.
   Google Scholar
• Rutherford M, Lambert P, Sweeting M, et al. NICE DSU Technical Support Document 21: flexible methods for survival analysis; 2021. [cited 2021 May 2]. Available from: http://nicedsu.org.uk/flexible-methods-for-survival-analysis-tsd/.
   Google Scholar
• Bullement A, Meng Y, Cooper M, et al. A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the national institute for health and care excellence: how did the initial best estimate compare to trial data subsequently made available? J Med Econ. 2019;22(3):205–214.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Guidance and advice list; 2021. [cited 2021 May 2]. Available from: https://www.nice.org.uk/guidance/published?type=ta.
   Google Scholar
• National Cancer Institute (NCI). NCI Dictionary of Cancer Terms 2018. [cited 2021 May 2]. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=772606.
   Google Scholar
• Fedorov S. GetData Graph Digitizer 2013. [cited 2018 June 1]. Available from: http://getdata-graph-digitizer.com/index.php.
   Google Scholar
• Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.
   PubMed Web of Science ®Google Scholar
• Jackson CH. flexsurv: a platform for parametric survival modeling in R. J Stat Softw. 2016;70:i08.
   PubMed Web of Science ®Google Scholar
• Royston P, Parmar MK. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002;21(15):2175–2197.
   PubMed Web of Science ®Google Scholar
• Bullement A, Latimer NR, Gorrod HB. Survival extrapolation in cancer immunotherapy: a validation-based case study. Value Health. 2019;22(3):276–283.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Technology appraisal guidance [TA581]: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma 2019. [cited 2021 Apr 2]. Available from: https://www.nice.org.uk/guidance/ta581.
   Google Scholar
• Othus M, Bansal A, Koepl L, et al. Accounting for cured patients in cost-effectiveness analysis. Value Health. 2017;20(4):705–709.
   PubMed Web of Science ®Google Scholar
• Othus M, Barlogie B, LeBlanc ML, et al. Cure models as a useful statistical tool for analyzing survival. Clin Cancer Res. 2012;18(14):3731–3736.
   PubMed Web of Science ®Google Scholar
• Office of National Statistics (ONS). National Life Tables. United Kingdom 2017-2018. [cited 2021 May 2]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesenglandreferencetables.
   Google Scholar
• Grant TS, Burns D, Kiff C, et al. A case study examining the usefulness of cure modelling for the prediction of survival based on data maturity. Pharmacoeconomics. 2020;38(4):385–395.
   PubMed Web of Science ®Google Scholar
• American Joint Committee on Cancer (AJCC). Cancer staging manual. 7th ed. New York: Springer-Verlag; 2010.
   Google Scholar
• Centers for Disease Control and Prevention (CDC). National life tables. United States of America; 2017. [cited 2020 Oct 26]. Available from: https://www.cdc.gov/nchs/data/nvsr/nvsr68/nvsr68_07-508.pdf.
   Google Scholar
• National Institute for Health and Care Excellence (NICE). Technology appraisal guidance [TA400]: Nivolumab in combination with ipilimumab for treating advanced melanoma 2016. [cited 2018 Apr 26]. Available from: https://www.nice.org.uk/guidance/ta400.
   Google Scholar
• Cooper M, Smith S, Williams T, et al., editors. How successful are standard and flexible extrapolation methods for the long-term projection of overall survival compared with trial data subsequently made available for cancer immunotherapies?. Orlando (FL): ISPOR; 2020.
   Google Scholar
• Ouwens MJ, Mukhopadhyay P, Zhang Y, et al. Estimating lifetime benefits associated with immuno-oncology therapies: challenges and approaches for overall survival extrapolations. Pharmacoeconomics. 2019;37(9):1129–1138.
   PubMed Web of Science ®Google Scholar
• Gray J, Sullivan T, Latimer NR, et al. Extrapolation of survival curves using standard parametric models and flexible parametric spline models: comparisons in large registry cohorts with advanced cancer. Med Decis Making. 2021;41(2):179–193.
   PubMed Web of Science ®Google Scholar
• Birnie R, Gladwell D, Cooper M, et al. Five learnings manufacturers should take from the latest NICE guidance on survival modelling 2021. [cited 2021 May 2]. Available from: https://www.bresmed.com/home/our-publications/five-learnings-manufacturers-should-take-from-the-latest-nice-guidance-on-survival-modelling/.
   Google Scholar
• Roth JA, Yuan Y, Othus M, et al. A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancer. J Med Econ. 2021;24(1):79–86.
   PubMed Web of Science ®Google Scholar